Copyright
©The Author(s) 2024.
World J Hepatol. Aug 27, 2024; 16(8): 1131-1144
Published online Aug 27, 2024. doi: 10.4254/wjh.v16.i8.1131
Published online Aug 27, 2024. doi: 10.4254/wjh.v16.i8.1131
Table 3 The risk effects of tissue inhibitor of metalloproteinase-3 expression in the cancerous tissues on the clinicopathological features of hepatocellular carcinoma
Risk effects | ORLTE/HTG1 | 95%CI | P value |
Higher AFP | 15.32 | 6.63-35.38 | 1.65 × 10-10 |
Higher tumor size | 3.47 | 1.75-6.87 | 3.69 × 10-4 |
Tumor dedifferentiation | 3.04 | 1.65-5.65 | 4.31 × 10-4 |
Higher TNM stage | 2.60 | 1.64-4.07 | 4.21 × 10-5 |
Higher MVD | 2.45 | 1.35-4.45 | 3.20 × 10-3 |
Higher risk of PVTT | 4.38 | 2.18-8.83 | 3.52 × 10-4 |
Higher risk of MVI | 3.24 | 1.71-6.14 | 3.20 × 10-4 |
-
Citation: Liang QJ, Long QQ, Tian FQ, Su QY, Zhu XY, Long XD. Tissue inhibitor of metalloproteinase-3 expression affects clini
copathological features and prognosis of aflatoxin B1-related hepatocellular carcinoma. World J Hepatol 2024; 16(8): 1131-1144 - URL: https://www.wjgnet.com/1948-5182/full/v16/i8/1131.htm
- DOI: https://dx.doi.org/10.4254/wjh.v16.i8.1131